TITLE

Cervical dysplasia regression induced by all-trans-retinoic acid

AUTHOR(S)
Sporn, Michael B.; Roberts, Anita B.
PUB. DATE
April 1994
SOURCE
JNCI: Journal of the National Cancer Institute;4/6/94, Vol. 86 Issue 7, p476
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Comments on F.L. Meyskens et al's report in the April 6, 1994 issue of the `Journal of the National Cancer Institute,' on how topical application of all-trans-retinoic acid (RA) can enhance regression of dysplasia of the uterine cervix. Basis for the conclusion; Significance of the findings for cancer research; Vitamin A metabolism to control gene transcription.
ACCESSION #
9609080714

 

Related Articles

  • Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with... Meyskens Jr., Frank L.; Surwit, Earl // JNCI: Journal of the National Cancer Institute;4/6/94, Vol. 86 Issue 7, p539 

    Presents the results of a randomized phase III trial to determine whether topically applied retinoic acid reversed moderate cervical intraepithelial neoplasia (CIN) II or severe CIN. Patient eligibility; Histological classification of dysplasia; Biopsy-cytology evaluation; Therapeutic regimen;...

  • How to reduce odds of treatment-caused infertility. Napoli, Maryann // HealthFacts;May96, Vol. 21 Issue 204, p3 

    Describes the complications from removing potentially cancerous cells from a woman's cervix. Impact of antibodies on sperm; Advantages of using the large loop treatment regimen; Diagnosis of atypical squamous cells.

  • Management of patients with atypical and low-grade pap smear abnormalities. Nuovo, Jim; Melnikow, Joy // American Family Physician;12/1/1995, Vol. 52 Issue 8, p2243 

    Discusses the management of patients with atypical and low-grade dysplasia and cervical cancer detected on Pap smear. Description of atypical and low-grade cervical abnormalities; Conservative management as an alternative to an ablative and excisional procedure; Arguments against a conservative...

  • Disappearing danger. Munson, Marty; Higbee, Beth // Prevention;Nov94, Vol. 46 Issue 11, p52 

    Offers results of a study on the effects of Retin-A on precancerous conditions (dysplasia) in women. Use of a cream containing all-trans-retinoic acid; Report in `Journal of the National Cancer Institute,' April 6, 1994; Implications for reversing or suppressing cancer at an early stage; Lack...

  • Better cost-effective treatment needed for cervical cancer.  // PharmacoEconomics & Outcomes News;7/1/2013, Issue 682, p6 

    The article discusses a research on cervical cancer (CC) treatment, in reference to the study "Is the Progression Free Survival Advantage of Concurrent Gemcitabine plus Cisplatin and Radiation followed by Adjuvant Gemcitabine and Cisplatin in Patients With Advanced CC Worth the Additional Cost?...

  • Vinegar screening technique reduced cervical cancer mortality by 31%. Southall, Jennifer R. // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p1 

    The article reports on a study which showed that biennial screening with acetic acid or vinegar has reduced cervical cancer mortality by 31 percent among women in India.

  • Erlotinib plus cisplatin chemoradiation induced high response rate in cervical cancer.  // Hem/Onc Today;6/25/2014, Vol. 15 Issue 12, p48 

    The article discusses the results of an open-label, single-site, phase 2 study which appeared in an article by Angélica Nogueira-Rodrigues, MD, of the Brazilian National Cancer Institute, in a 2014 issue of the journal "Cancer," revealing the promising activity of the addition of erlotinib to...

  • El tratamiento actual del cáncer cervicouterino. García Noriega, José; Noriega Limón, José // Ginecologia y Obstetricia de Mexico;feb2008, Vol. 76 Issue 2, p131 

    No abstract available.

  • Addition of tirapazamine to cisplatin chemoradiotherapy did not improve PFS in cervical cancer. Byrne, Jennifer; Southall, Jennifer; Todak, Alexandra // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p14 

    The article highlights a Phase III trial published in the "Journal of Clinical Oncology," which demonstrated that the addition of the hypoxic cell sensitizer tirapazamine to a cisplatin chemotherapy regimen did not lead to better progression-free survival (PFS) rates for cervical cancer patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics